3651 results for «211»
3651 results
TAVI: vascular complications
16 Nov 2025 – From PCR London Valves 2025
This session examines vascular complications associated with transfemoral TAVI procedures, featuring challenging cases such as initial procedural obstacles, complex post-TAVI vascular events, and unusual complications. It also explores advanced techniques like intravascular lithotripsy to optimize TAVI outcomes in patients with severe calcific iliofemoral disease.
TAVI valve-in-valve - Challenging clinical scenarios
17 Nov 2025 – From PCR London Valves 2025
This session focuses on the complexities of valve-in-valve TAVI procedures, highlighting challenging clinical scenarios such as managing severely regurgitant rapid deployment valves and degenerated stentless bioprostheses. It provides detailed insights into overcoming procedural barriers and strategies for complex valve-in-valve transcatheter aortic valve replacement (TAVR) interventions.
TAVI: high coronary risk - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents advanced strategies to mitigate high coronary risk during valve-in-valve TAVR procedures, including the LLAMACORN technique and chimney stenting to prevent coronary obstruction. It discusses management of misaligned prostheses, complex aortic and coronary anatomies, and innovative approaches such as stent crush techniques to ensure...
TAVI: alternative access
17 Nov 2025 – From PCR London Valves 2025
This session addresses alternative access routes for TAVI in patients with challenging vascular anatomies. It includes innovative approaches such as transapical TAV-in-TAV procedures, transcaval implantation in emergency settings, and techniques for patients with hostile iliofemoral access, showcasing adaptive strategies when conventional access is not feasible.
TAVI: challenging anatomies
17 Nov 2025 – From PCR London Valves 2025
This session explores the management of challenging anatomical conditions in TAVI procedures. Topics include strategies for difficult self-expandable valve delivery angles, addressing complications occurring during and after TAVI, and approaches for patients with severe kyphosis or complex structural abnormalities such as aneurysms and septal anomalies.
Complex mitral and tricuspid TEER
16 Nov 2025 – From PCR London Valves 2025
This session highlights complex cases in mitral and tricuspid transcatheter edge-to-edge repair (TEER), addressing challenges such as septal obstacles in patients with old atrial septal occluders, management of residual atrial septal defects post-mitral valve-in-ring replacement, and innovative multidisciplinary approaches. It also covers hybrid transapical mitral valve-in-valve...
The index valve matters: optimal index TAVI for a lifetime of possibilities
18 Nov 2025 – From PCR London Valves 2025
Discover how thoughtful index valve selection and implantation techniques can shape the long-term management of patients undergoing TAVI. This PCR London Valves 2025 session highlights treatment considerations for low- and intermediate-risk patients, explores how valve choice affects the feasibility of future interventions, and examines strategies to...
The next frontier in LAA closure: innovations and opportunities
17 Nov 2025 – From PCR London Valves 2025
Explore the forefront of left atrial appendage (LAA) closure with this session focusing on the latest innovations and clinical opportunities. Topics include recent data on WATCHMAN FLX PRO and VersaCross Connect systems, workflow strategies to improve procedural efficiency, and discussions on upcoming clinical trials such as...
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
